Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space, but ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics' lead clinical stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need.

Biotechnology

Peptilogics

Jonathan Steckbeck

Marc Lesnick

Albert Fonticiella

Steve Kulp

Atul Deshpande Ph.d.

David Huang

Bradd Picone

Nicholas Pachuda

Nick Nystrom

The board of directors at Peptilogics have experience in a variety of fields including precision genetic medicines, oncology, and high-throughput low-cost NGS library preparation technology. They also have a variety of educational backgrounds, including human genetics and genomics from the University of Pittsburgh and the National Human Genome Research Institute - NIH.

Board of Directors

Leadership Team

CEO and Executive Team

Board of Directors

About

Team members

Other teams at Peptilogics

Leadership Team

CEO and Executive Team